Trending NewsTrending NewsNASDAQ:ALDX Aldeyra Therapeutics (ALDX) Stock Price, News & Analysis $1.71 -0.07 (-3.93%) Closing price 04:00 PM EasternExtended Trading$1.69 -0.02 (-1.17%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Aldeyra Therapeutics Stock (NASDAQ:ALDX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Aldeyra Therapeutics alerts:Sign Up Key Stats Today's Range$1.68▼$1.7850-Day Range$1.24▼$2.2352-Week Range$1.07▼$6.18Volume883,118 shsAverage Volume877,917 shsMarket Capitalization$103.15 millionP/E RatioN/ADividend YieldN/APrice Target$5.50Consensus RatingHold Company Overview Aldeyra Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapies for immune-mediated diseases. The company’s research efforts center on targeted alkenals, a class of reactive aldehyde species that play a key role in inflammatory pathways. By selectively modulating these pathways, Aldeyra aims to address both ocular and systemic indications with high unmet medical need. The company’s lead product candidate, reproxalap, is being investigated in several ophthalmic disorders, including dry eye disease, allergic conjunctivitis and non-infectious anterior uveitis. Aldeyra is also developing ADX-2191, an intravitreal formulation targeting proliferative vitreoretinopathy, a serious complication of retinal detachment surgery. In addition to its ophthalmology pipeline, Aldeyra has earlier-stage programs exploring systemic indications where reactive aldehyde species contribute to inflammation and tissue damage. Founded in 2009 and headquartered in Lexington, Massachusetts, Aldeyra is led by a management team with extensive experience in ophthalmology and biopharmaceutical development. Under the leadership of Chief Executive Officer Fredric A. Hargreaves, the company collaborates with clinical research centers across North America and Europe to advance its pipeline through late-stage clinical trials. Aldeyra’s strategy emphasizes rigorous clinical validation, strategic partnerships and readiness for commercial launch upon regulatory approval.AI Generated. May Contain Errors. Read More Aldeyra Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks70th Percentile Overall ScoreALDX MarketRank™: Aldeyra Therapeutics scored higher than 70% of companies evaluated by MarketBeat, and ranked 218th out of 867 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingHold Consensus RatingAldeyra Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 2 hold ratings, and 1 sell rating.Upside PotentialAldeyra Therapeutics has a consensus price target of $5.50, representing about 221.6% upside from its current price of $1.71.Amount of Analyst CoverageAldeyra Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Aldeyra Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Aldeyra Therapeutics are expected to grow in the coming year, from ($0.43) to ($0.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aldeyra Therapeutics is -3.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aldeyra Therapeutics is -3.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAldeyra Therapeutics has a P/B Ratio of 2.44. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Aldeyra Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.90% of the float of Aldeyra Therapeutics has been sold short.Short Interest Ratio / Days to CoverAldeyra Therapeutics has a short interest ratio ("days to cover") of 8.49.Change versus previous monthShort interest in Aldeyra Therapeutics has recently increased by 2.96%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAldeyra Therapeutics does not currently pay a dividend.Dividend GrowthAldeyra Therapeutics does not have a long track record of dividend growth. News and Social Media3.1 / 5News Sentiment0.01 News SentimentAldeyra Therapeutics has a news sentiment score of 0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 16 news articles for Aldeyra Therapeutics this week, compared to 6 articles on an average week.Search Interest10 people have searched for ALDX on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.MarketBeat Follows2 people have added Aldeyra Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership4.6 / 5Insider TradingAcquiring Shares Cluster Insider Buying2 insiders have purchased shares of Aldeyra Therapeutics in the last three months. Multiple insiders buying is a strong bullish signal.Net Insider BuyingOver the last three months, insiders have purchased a net $105,100.00 in company stock, which represents 0.1019% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Aldeyra Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $105,100.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders9.60% of the stock of Aldeyra Therapeutics is held by insiders.Percentage Held by Institutions59.71% of the stock of Aldeyra Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Aldeyra Therapeutics' insider trading history. Receive ALDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aldeyra Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ALDX Stock News HeadlinesALDX INVESTOR ALERT: Holzer & Holzer, LLC Reminds Investors of the May 29, 2026 Lead Plaintiff Deadline in the Aldeyra Therapeutics, Inc. Securities Class ActionMay 27 at 8:00 AM | globenewswire.comAldeyra Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ALDXMay 27 at 3:44 AM | prnewswire.comYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.May 27 at 1:00 AM | Profits Run (Ad)ALDEYRA DEADLINE FRIDAY MAY 29th: Bragar Eagel & Squire, P.C. Urgently Reminds Aldeyra Therapeutics, Inc. Investors with Large Losses to Contact the Firm Regarding Their Rights Before May 29thMay 26 at 5:45 PM | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aldeyra Therapeutics, Inc. Of Class Action Lawsuit and Upcoming Deadlines – ALDXMay 26 at 4:06 PM | globenewswire.comPortnoy Law Firm Announces Class Action on Behalf of Aldeyra Therapeutics, Inc. InvestorsMay 26 at 9:05 AM | globenewswire.comALDX Shareholder Alert: Aldeyra Therapeutics, Inc. Securities Class Action Lawsuit - Investors Should Contact The Gross Law FirmMay 26 at 9:00 AM | prnewswire.comALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law FirmMay 25 at 10:04 AM | globenewswire.comSee More Headlines ALDX Stock Analysis - Frequently Asked Questions How have ALDX shares performed this year? Aldeyra Therapeutics' stock was trading at $5.18 on January 1st, 2026. Since then, ALDX stock has decreased by 67.0% and is now trading at $1.71. How were Aldeyra Therapeutics' earnings last quarter? Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) posted its earnings results on Thursday, May, 7th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.13) by $0.07. When did Aldeyra Therapeutics IPO? Aldeyra Therapeutics (ALDX) raised $16 million in an initial public offering (IPO) on Friday, April 11th 2014. The company issued 1,500,000 shares at a price of $10.00-$12.00 per share. Who are Aldeyra Therapeutics' major shareholders? Top institutional investors of Aldeyra Therapeutics include Renaissance Technologies LLC (1.43%), Dimensional Fund Advisors LP (1.03%), Bank of America Corp DE (0.36%) and Bank of New York Mellon Corp (0.23%). Insiders that own company stock include Perceptive Advisors Llc, Todd C Brady, Stephen Machatha, Richard Douglas, Bruce Greenberg and Michael Alfieri. View institutional ownership trends. How do I buy shares of Aldeyra Therapeutics? Shares of ALDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Aldeyra Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aldeyra Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), Viking Therapeutics (VKTX), Alibaba Group (BABA) and Netflix (NFLX). Company Calendar Last Earnings5/07/2026Today5/27/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 ALDX's financial health is in the Red zone, according to TradeSmith. ALDX has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ALDX CIK1341235 Webwww.ampliphibio.com Phone781-761-4904Fax781-270-0630Employees10Year Founded2004Price Target and Rating Average Price Target for Aldeyra Therapeutics$5.50 High Price Target$9.00 Low Price Target$2.00 Potential Upside/Downside+221.6%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($0.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$33.85 million Net MarginsN/A Pretax MarginN/A Return on Equity-57.34% Return on Assets-36.33% Debt Debt-to-Equity RatioN/A Current Ratio2.72 Quick Ratio2.72 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.70 per share Price / Book2.44Miscellaneous Outstanding Shares60,320,000Free Float54,530,000Market Cap$103.15 million OptionableOptionable Beta1.16 Social Links Beginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:ALDX) was last updated on 5/27/2026 by MarketBeat.com Staff. From Our PartnersThe 1934 playbookIn 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...American Alternative | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredRead now. Do not delete. You’ve been warned.Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...Porter & Company | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aldeyra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aldeyra Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
